Loading quotes...
Forecast
| Buy |
2 |
| Hold |
1 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 1.93M | 990.84% |
| Gross profit | 1.2M | 1,417.31% |
| Net profit | -1.41M | 83.89% |
| EBITDA | -1.41M | 50.98% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €9.22M |
Number of shares | 7.56M |
52-week high/low | €4.05 - €1.21 |
| Dividends | No |
Beta | 0.59 |
P/E ratio | -0.60 |
PEG ratio | -0.01 |
P/B ratio | 2.64 |
P/S ratio | 3.02 |
Company profile
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
| Name | SiNtx Technologies |
| CEO | Eric K. Olson |
| Headquarters | Salt Lake City,
ut USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 02/13/2014 |
| Employees | 32 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | SINT |
Frankfurt | 111N.F |
London | 0A8S.L |
München | 111N.MU |